Why Is Cancer Drug Revlimid So Expensive?
Why Is Cancer Drug Revlimid So Expensive?
A personal investigation by ProPublica reporter David Armstrong into the exorbitant price of Revlimid, a crucial drug for his own multiple myeloma treatment. The article traces the drug's history from its controversial thalidomide origins to its current status as a blockbuster cancer treatment. It exposes the strategies employed by drugmaker Celgene, including patent manipulation and suppression of generic competition, that led to the drug's price being hiked 26 times, costing nearly $1,000 per pill despite a manufacturing cost of 25 cents.
Note
a sobering story fueled by logic that avoids maximizing accessibility as a first order concern.
to end the article with the price of generics offering little to no savings is a punch to the gut as late stage capitalism reals its ugly head and declares an empty victory for the few.
Published
Summary
Image
